Wall Street equity research analysts covering Pfizer Inc. (NYSE: PFE) maintain a median 12-month consensus price target hovering around $28 per share, with individual institutional forecasts ranging from a low estimate of roughly $25 to a high bull-case target of $36. This target reflects cautious sentiment as the pharmaceutical giant moves past pandemic-era product revenue peaks, focusing instead on rebuilding its core oncology and specialized therapeutics pipeline, managing debt maturities, and sustaining its high dividend yield.